This medical animation shows a novel cancer therapy moa of AT-101 targeted lytic peptide that binds to cancer cells and kills them on contact.
A28 Therapeutics has developed a platform technology based on combining the lytic peptide unit to various targeting units that bind to a host of different receptors found commonly on cancer cells. The lytic peptide unit remains the same allowing for rapid killing of cancer cells while leaving healthy cells unharmed.
This pipeline technology is currently not approved.
For more information about custom medical animations, visit www.amerra.com/.